APA

Coller J. K., Bowen J. M., Ball I. A., Wardill H. R., van Sebille Y. Z. A., Stansborough R. L., Lightwala Z., Wignall A., Shirren J., Secombe K. & Gibson R. J. (20170606). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. : Cancer chemotherapy and pharmacology.

Chicago

Coller Janet K, Bowen Joanne M, Ball Imogen A, Wardill Hannah R, van Sebille Ysabella Z A, Stansborough Romany L, Lightwala Zenab, Wignall Anthony, Shirren Joseph, Secombe Kate and Gibson Rachel J. 20170606. Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. : Cancer chemotherapy and pharmacology.

Harvard

Coller J. K., Bowen J. M., Ball I. A., Wardill H. R., van Sebille Y. Z. A., Stansborough R. L., Lightwala Z., Wignall A., Shirren J., Secombe K. and Gibson R. J. (20170606). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. : Cancer chemotherapy and pharmacology.

MLA

Coller Janet K, Bowen Joanne M, Ball Imogen A, Wardill Hannah R, van Sebille Ysabella Z A, Stansborough Romany L, Lightwala Zenab, Wignall Anthony, Shirren Joseph, Secombe Kate and Gibson Rachel J. Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. : Cancer chemotherapy and pharmacology. 20170606.